129 results about "Decreased surfactant" patented technology

The present invention provides spreading agents based on sequence-specific oligomers comprising a peptoid, a peptide-peptoid chimera, a retropeptoid or a retro(peptoid-peptide) chimera, and methods for using the same, including for the treatment of respiratory distress of the lungs. The spreading agents are sequence-specific oligomers, including retrosequence-specific oligomers, based on a peptide backbone, that are designed as analogs of surfactant protein-B or surfactant protein-C.

The present invention is a foamable alcohol health, beauty, skin care, nail care and / or haircare product. Alcohol, such as ethyl alcohol is combined with a fluoro-surfactant, at least one active ingredient and water. Other ingredients can be added. The fluoro-surfactant reduces the surface tension of the alcohol allowing it to be foamed without reducing the effectiveness of the alcohol as a carrier for the active ingredient or the efficacy of the active ingredient(s). The inventive mixture foams when dispensed as an aerosol or pumped through a foam pump. The pump or other dispenser doses the alcohol. The foam is easy to apply, and liquefies as a user smears it on a surface.

A powdered pulmonary surfactant preparation containing a hydrophobic protein serving as a pulmonary surfactant is obtained by spray drying an organic solution or suspension containing a hydrophobic protein serving as a pulmonary surfactant and possibly other components. Obtained power preparations exhibit very good stability under storage, are easy to reconstitute and are also suitable for administration by inhalation.

Synthetic pulmonary surfactant compositions comprising dipalmitoyl phosphatidylcholine, phosphatidylglycerol, and essentially neutral lipid, and having essentially no 1-palmitoyl 2-oleoyl phosphatidylglycerol and essentially no palmitic acid are provided. Methods for treating respiratory disease are also provided comprising administering a therapeutically effective amount of a synthetic pulmonary surfactant comprising dipalmitoyl phosphatidylcholine, phosphatidylglycerol, and essentially neutral lipid, and having essentially no 1-palmitoyl 2-oleoyl phosphatidylglycerol and essentially no palmitic acid.

The present invention is a foamable alcohol having at least one active ingredient. The active ingredient can be a prescription or non-prescription drug or medication. It either works on the skin or is absorbed transdermally and works on the body. Alcohol, such as ethyl alcohol is combined with a fluoro-surfactant, at least one active ingredient and water. Optionally, inactive ingredients can be added. The fluoro-surfactant reduces the surface tension of the alcohol allowing it to be foamed without reducing the effectiveness of the alcohol as a carrier for the active ingredient or the efficacy of the active ingredient(s). The inventive mixture foams when dispensed as an aerosol or pumped through a foam pump. The pump or other dispenser doses the alcohol. The foam is easy to apply, and liquefies as a user smears it on a surface.

The present invention relates generally to a method of diagnosing, predicting or monitoring the development or progress of heart failure in a mammal and, more particularly, to a method of diagnosing, predicting or monitoring the development or progress of congestive heart failure in a mammal. The present invention contemplates a method for detecting heart failure by screening for the systemic presence of pulmonary surfactant protein in a subject. The present invention further provides a method for diagnosing or monitoring conditions associated with or characterised by the onset of heart failure, in particular congestive heart failure. Also provided are diagnostic agents useful for detecting one or more surfactant proteins.

A method and system according to preferred embodiments of the present invention allows optimizing the dispensing of aerosol medicaments. In particular the system according to a preferred embodiment of the present invention allows the administration of an exogenous pulmonary surfactant to very young patients (e.g. preterm neonates). A catheter 101 conveys atomized surfactant directly to the retro-pharyngeal region in order to increase efficiency of the medicament administration without being invasive: this is particularly important for very young patients, such as pre-term born neonates suffering from neonatal Respiratory Distress Syndrome (nRDS). According to a preferred embodiment of the present invention the catheter is made of biocompatible flexible material (e.g. plastic material). It is possible to couple the catheter with a rigid scaffolding (e.g. metallic) to increase stiffness of the device and to improve easiness of positioning operations. In a preferred embodiment of the present invention the delivery of the atomized medicament is done by means of an air blasting technique.

The invention relates to the combination of a pulmonary surfactant and a TNF-derived peptide and its use for the treatment of respiratory disease.

The invention discloses an ambroxol hydrochloride oral solution and a preparation method thereof, and relates to a preparation method of western medicine, in particular to a medical production formula used for curing bronchitis and a preparation method thereof; the preparation method comprises the following steps: sucrose, preservatives and purified water are dissolved in a mixing mode so as to prepare simple syrup; the ambroxol hydrochloride, corrigents and preservatives are dissolved by the purified water so as to prepare ambroxol hydrochloride solution; the ambroxol hydrochloride solution and the simple syrup are stirred and mixed evenly, the corrigents and the preservatives are added successively and discontinuously and then the purified water is added to adjust the concentration. The invention has simple and reasonable process, and is easy to operate practically and the produced products have good stability; the products can used as common phlegm-eliminating drugs, has functions of increasing the liquid level of the respiratory tract, reducing mucus secretion, enhancing the secretion of pulmonary surfactant and the movement of cilium and preventing cough to a certain extent, and is applicable to acute respiratory disease and chronic respiratory disease, such as ropy sputum and difficult cough caused by acute bronchitis and chronic bronchitis, bronchial asthma and pulmonary tuberculosis, etc.

The invention relates to the combined administration of a pulmonary surfactant and a PDE5 inhibitor for the treatment of a disease in which pulmonary surfactant malfunction and / or phosphodiesterase 5 (PDE5) activity is detrimental.

The invention provides a preparation method of a carbon-loaded platinum-based alloy catalyst, which comprises the following steps: adding a carbon carrier into an aqueous solution of a platinum-containing precursor compound and a transition metal-containing precursor compound; and adjusting the pH value in an ice bath, quickly freezing and drying, carrying out heat treatment in a reducing atmosphere, and carrying out after-treatment. The prepared catalyst is good in alloy state, the catalytic activity exceeds that of common platinum-carbon catalysis by three times or above, no surfactant is used in the preparation method, use of chemical reagents is reduced, and industrial production is better facilitated.

The invention relates to reconstituted surfactants consisting of artificial phospholipids and peptides able to lower the air-liquid surface tension, more particularly to reconstituted surfactants, comprising special phospholipid mixtures and artificial peptides which are analogues of the natural surfactant SP-C protein for the treatment of respiratory distress syndrome (RDS) and other diseases relates to pulmonary surfactant dysfunctions.

The present invention is directed to methods and compositions for improving pulmonary surfactant catabolism. More specifically, the specification describes methods and compositions for making and using a lysosomal phospholipase A2 in methods for the diagnosis, and treatment of disorders of phospholipid catabolism such as pulmonary alveolar proteinosis.

The present invention provides an anti-aging cerium-zirconium composite oxide. The cerium-zirconium composite oxide has a specific surface area of 80 m<2> / g or more, a pore volume of 0.55-0.80 ml / g, an oxygen storage capacity of 500-1200 [mu]mol O2 / g and two-pore group distributed apertures, wherein the diameter of the first pore group is concentrated at 3-10 nm, and the diameter of the second pore group is concentrated at 15-80 nm. The cerium-zirconium composite oxide provided by the invention has a significant anti-aging activity and a good low-temperature catalytic activity, and can be used for catalyzing hydrocarbons, carbon oxides and / or nitrogen oxides in mobile source exhaust gas. A preparation method of the cerium-zirconium composite oxide, provided by the invention, does not use a surfactant, and reduces sewage discharge, so the method is green and environmentally friendly; an ionic liquid and anhydrous ethanol can be recovered by simple distillation, so the cost is greatly reduced, and the method is particularly suitable for industrial production; and the composite oxide with uniform element crystal lattice doping distribution and no phase separation is obtained, so the preparation method is of great significance to study mobile source exhaust gas treatment purifiers containing the cerium-zirconium composite oxide.

The present invention relates to pharmaceutical and medical technologies, and more particularly to novel nanobodies against pulmonary surfactant protein A (SP-A) and their preparation methods. The nanobodies of the present invention comprises an amino acid sequence having certain formula. The present invention also relates to nucleic acid sequences encoding the nanobodies, their preparation method and their applications. Immunohistochemistry and in vivo imaging show that the nanobodies of the present inventions have high lung-targeting specificity.

The present invention is directed to methods and compositions for improving pulmonary surfactant catabolism. More specifically, the specification describes methods and compositions for making and using a lysosomal phospholipase A2 in methods for the diagnosis, and treatment of disorders of phospholipid catabolism such as pulmonary alveolar proteinosis.

The present invention is directed to a reconstituted surfactant comprising a phospholipid mixture, and a combination of particular analogues of the native surfactant protein SP-C with analogues of the native surfactant protein SP-B. The invention is also directed to pharmaceutical compositions and kits thereof and to its use for the treatment or prophylaxis of RDS and other respiratory disorders.

The present invention provides a polyoxyethylene alkyl ether sulfate or alkyl sulfate that has good fluidity in a wide range of temperatures even if it contains a high concentration of polyoxyethylene alkyl ether sulfate or alkyl sulfate, does not cause viscosity increase or gelation when diluted, and does not Surfactant compositions used for the production of skin cleansers or hair cleansers that degrade the intrinsic properties of surfactants. The surfactant composition of the present invention contains the following components (A), (B) and (C), (A) represented by the general formula R1O(CH2CH2O)nSO3M is polyoxyethylene alkyl ether sulfate or alkyl sulfate , in the formula, R1 represents a saturated or unsaturated hydrocarbon group with 8 to 18 carbon atoms, the average added mole number n represents the number of 0 to 5, and M represents an alkali metal atom, alkanolamine or ammonium; (B) One or more glyceryl ethers or diglyceryl ethers having an alkyl or alkenyl group having 4 to 24 carbon atoms; (C) water-soluble salts, the content of component (A) being 40% by weight or more.

The invention relates to reconstituted surfactants consisting of artificial phospholipids and peptides able to lower the air-liquid surface tension, more particularly to reconstituted surfactants comprising special phospholipid mixtures and artificial peptides which are analogues of the natural surfactant SP-C protein for the treatment of respiratory distress syndrome (RDS) and other diseases relating to pulmonary surfactant dysfunctions.

The present invention relates to pharmaceutical and medical technologies, and more particularly to novel nanobodies against pulmonary surfactant protein A (SP-A) and their preparation methods. The nanobodies of the present invention comprises an amino acid sequence having certain formula. The present invention also relates to nucleic acid sequences encoding the nanobodies, their preparation method and their applications. Immunohistochemistry and in vivo imaging show that the nanobodies of the present inventions have high lung-targeting specificity.

The present invention relates to a surfactant moryoupe and the preparation method and the application of the surfactant, which pertains to the technical field of pharmaceutical industry. The composition is made by extraction, purification and other steps of the tissues of bivalves mollusks, the composition contains rich phospholipid complex of the seafood which is composed of polyunsaturated fatty acids, wherein, the composition includes plasmalogen, active short-chain peptides and amino acids etc. The composition of the present invention has the surface activity of the surfactant, which can be used for preparing the drugs for replacement, therapy during the lack of pulmonary surfactants; furthermore, the invention has no immunogenicity.

The present invention is directed to a reconstituted surfactant comprising a lipid carrier, a polypeptide analog of the native surfactant protein SP-C, and a polypeptide analog of the native surfactant protein SP-B. The invention is also directed to the pharmaceutical compositions thereof and to a use thereof in the treatment or prophylaxis of RDS and other respiratory disorders.

The invention relates to a method for treatment of a surfactant, in particular a pulmonary surfactant. The method is further established in that the surfactant is treated with a lipid sequestrating or cholesterol sequestrating surfactant treatment agent, in which given, in particular neutral lipids or cholesterol are selectively sequestrated by means of the surfactant treatment agent, such that the effect of the lipids and / or the effect of the cholesterol on the surfactant is reduced or reversed.The invention further relates to a method for producing a surfactant treatment agent, in particular a pulmonary surfactant treatment agent. The invention also relates to a surfactant treatment agent and a use of a treatment agent for treating a surfactant, in particular a pulmonary surfactant and a use of cyclodextrins.

Lyophilized pulmonary surfactants having an increased specific surface area and porosity are described. Methods of making the lyophilized pulmonary surfactants are also described.

The invention provides an organ chip and a method for evaluating the interaction of nanoparticles and a pulmonary surfactant layer based on an organ chip technology. The chip consists of four layers and is formed by bonding and sealing a topmost layer of PDMS, a second layer of a hydrophilic treated PET film, a third layer of PDMS and a fourth layer of a glass sheet from top to bottom; the chip includes an extracellular matrix inlet channel, a nanoparticle inlet channel, a waste liquid outlet channel, a gas supply channel, a pulmonary epithelial cell culture chamber, an aspirating chamber, andan aspirating channel. The chip is inoculated with pulmonary epithelial cells, and the pulmonary surfactant layer is produced by the pulmonary epithelial cells after culture is performed for a certain period of time; nanoparticles are added into the pulmonary epithelial cell culture chamber, and an evaluation model of the interaction between the nanoparticles and the pulmonary surfactant in vitrois established. The evaluation model of the interaction between the nanoparticles and the pulmonary surfactant based on the chip not only can simulate the effect of the nanoparticles on the pulmonarysurfactant layer, can monitor the layer in real time, but also can be used for evaluating the damage of drugs to the pulmonary epithelial cells.

The present invention is directed to a novel method for increasing the expression of pulmonary surfactant protein-B in an infant. The method comprises administration of a therapeutically effective amount of DHA and ARA, alone or in combination with one another, to the infant.

The invention discloses an aptamer LC (liquid crystal) biosensor for detecting pulmonary surfactant protein A as well as a preparation and detection method of the aptamer LC biosensor. The method is based on a detecting platform of aptamers, and when an aldehydation slide surface is modified with the aptamers of the pulmonary surfactant protein A with the optimum concentration, slight topological change on the slide surface almost has no influence on a sensing system and a dark background under a polarizing microscope is still kept; when the pulmonary surfactant protein A is present, the pulmonary surfactant protein aptamers can react with the pulmonary surfactant protein A, a structure similar to double-stranded DNA is formed, so that a topological structure of the slide surface is greatly changed, the LC orientation can be disturbed by the change, as a result, an LC optical image changing from darkness to colorfulness under the polarizing microscope is shown, and the pulmonary surfactant protein A can be detected; the LC biosensor is simple in structure and convenient and has quite high sensitivity and quite good selectivity, and with application of the method, the limit of detection of the pulmonary surfactant protein A is 5 nmol.L<-1>.

The invention belongs to the technical field of membranes, and relates to a preparation method of a novel composite loose nanofiltration membrane. According to the preparation method of the novel composite loose nanofiltration membrane provided by the invention, a loose and uniform net-shaped structure is formed in a synergetic cross-linking manner of aromatic acid, tannic acid and a water-soluble high-molecular polymer, and a surfactant is adopted to reduce the tension of a water surface, improve the hydrophilicity of the surface of the membrane and promote the proceeding of a cross-linking reaction; meanwhile, the tannic acid can enhance the combination degree between a separation layer and a base membrane; the tannic acid and a cross-linked structure of the high-molecular polymer have higher mechanical strength, the stability of the membrane is enhanced; and the tannic acid, aromatic acid and the high-molecular polymer are synergistically cross-linked to form a cross-linked structure with a larger pore size more easily, so that the membrane with uniform interception pore size and high water flux can be prepared. According to the preparation method provided by the invention, through simple and convenient operation steps, a better effect is realized under the condition that the raw materials and the preparation process are greatly simplified, and the application range of the composite membrane is widened.